2,248 Shares in Novartis AG (NYSE:NVS) Acquired by RVW Wealth LLC

RVW Wealth LLC purchased a new position in Novartis AG (NYSE:NVS) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 2,248 shares of the company’s stock, valued at approximately $251,000.

Several other institutional investors also recently modified their holdings of NVS. Continuum Advisory LLC lifted its holdings in shares of Novartis by 10.3% during the fourth quarter. Continuum Advisory LLC now owns 1,021 shares of the company’s stock valued at $99,000 after purchasing an additional 95 shares during the last quarter. Intergy Private Wealth LLC lifted its stake in Novartis by 3.9% during the first quarter. Intergy Private Wealth LLC now owns 2,757 shares of the company’s stock valued at $307,000 after buying an additional 104 shares in the last quarter. Keudell Morrison Wealth Management boosted its holdings in shares of Novartis by 3.8% in the first quarter. Keudell Morrison Wealth Management now owns 2,828 shares of the company’s stock worth $315,000 after buying an additional 104 shares during the period. D Orazio & Associates Inc. increased its position in shares of Novartis by 2.9% in the first quarter. D Orazio & Associates Inc. now owns 3,795 shares of the company’s stock worth $423,000 after acquiring an additional 108 shares in the last quarter. Finally, Opal Wealth Advisors LLC raised its holdings in shares of Novartis by 4.7% during the first quarter. Opal Wealth Advisors LLC now owns 2,515 shares of the company’s stock valued at $280,000 after acquiring an additional 112 shares during the period. Institutional investors own 13.12% of the company’s stock.

Novartis Price Performance

NYSE NVS opened at $116.72 on Thursday. The company has a 50 day simple moving average of $117.87 and a 200-day simple moving average of $111.44. Novartis AG has a 52-week low of $96.06 and a 52-week high of $124.83. The firm has a market capitalization of $246.56 billion, a price-to-earnings ratio of 16.99, a price-to-earnings-growth ratio of 1.65 and a beta of 0.59. The company has a debt-to-equity ratio of 0.53, a current ratio of 0.82 and a quick ratio of 0.62.

Novartis (NYSE:NVS) last released its earnings results on Thursday, July 17th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. Novartis had a net margin of 25.64% and a return on equity of 41.08%. The company had revenue of $14.05 billion during the quarter, compared to the consensus estimate of $13.94 billion. During the same quarter in the prior year, the firm earned $1.97 EPS. The company’s revenue was up 12.3% compared to the same quarter last year. Equities research analysts predict that Novartis AG will post 8.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, BNP Paribas raised shares of Novartis to a “strong-buy” rating in a research note on Tuesday, April 15th. Three analysts have rated the stock with a sell rating, six have given a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Novartis currently has a consensus rating of “Hold” and a consensus target price of $123.67.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.